Restrata
Surgical, traumatic, and chronic wound management (e.g., diabetic foot ulcers)
ApprovedCommercial
Key Facts
Indication
Surgical, traumatic, and chronic wound management (e.g., diabetic foot ulcers)
Phase
Approved
Status
Commercial
Company
About Acera Surgical
Acera Surgical is a private medical device company pioneering electrospun nanofiber technology for soft tissue repair and regenerative medicine. Its flagship product, Restrata, is the first fully synthetic electrospun fiber matrix indicated for wound management, supported by Level I clinical evidence. The company was recently acquired by Solventum (spun off from 3M), providing significant commercial and strategic resources. Acera's platform offers a unique, animal-free alternative to traditional biologic scaffolds, targeting a broad range of surgical and chronic wound applications.
View full company profile